Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5
|
pubmed:dateCreated |
1997-8-18
|
pubmed:abstractText |
It would be important to estimate in advance the risk of recurrent thrombosis. Deficiencies of antithrombin, protein C or protein S, or resistance to activated protein C are associated with a biochemically detectable prethrombotic state. It is thus far unknown whether in patients with a history of thromboembolism but without a defined clotting abnormality a heightened coagulation activation is detectable. We investigated the value of prothrombin fragment F1+2 (F1+2) as a predictor of recurrent venous thromboembolism. Furthermore, we compared the F1+2 levels of thrombosis patients without a defined clotting defect to those of Factor V Leiden patients with a history of venous thrombosis and to those of healthy controls. 180 patients without a defined clotting abnormality and 73 patients with Factor V Leiden were prospectively followed after discontinuation of oral anticoagulants for venous thrombosis and F1+2 was measured at regular intervals. Recurrent venous thromboembolism occurred in 23 (9%) of the 253 patients. Before or at several time points after oral anticoagulants, no significant difference in F1+2 levels was found in patients with and without recurrent thrombosis. F1+2 levels at 3 weeks and prior to recurrence were not significantly different in both patient groups. Over a one-year observation period, F1+2 levels of both patients with and without Factor V Leiden were higher than those of the controls. No difference in F1+2 was seen between patients with and without Factor V Leiden. We conclude that monitoring of F1+2 is not suitable for identification of individuals at risk of recurrent venous thrombosis. Permanent hemostatic system activation is detectable both in patients with a defined abnormality of the clotting system and in patients in whom a particular defect has not (yet) been identified.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticoagulants,
http://linkedlifedata.com/resource/pubmed/chemical/Factor V,
http://linkedlifedata.com/resource/pubmed/chemical/Peptide Fragments,
http://linkedlifedata.com/resource/pubmed/chemical/Protein Precursors,
http://linkedlifedata.com/resource/pubmed/chemical/Prothrombin,
http://linkedlifedata.com/resource/pubmed/chemical/factor V Leiden,
http://linkedlifedata.com/resource/pubmed/chemical/prothrombin fragment 1,
http://linkedlifedata.com/resource/pubmed/chemical/prothrombin fragment 2
|
pubmed:status |
MEDLINE
|
pubmed:month |
May
|
pubmed:issn |
0340-6245
|
pubmed:author |
pubmed-author:BialonczykCC,
pubmed-author:EichingerSS,
pubmed-author:HirschlMM,
pubmed-author:KyrleP APA,
pubmed-author:LechnerKK,
pubmed-author:MannhalterCC,
pubmed-author:MelichartMM,
pubmed-author:PabingerII,
pubmed-author:SchneiderBB,
pubmed-author:SpeiserWW,
pubmed-author:StümpflenAA,
pubmed-author:TraxlerGG,
pubmed-author:WeltermannAA
|
pubmed:issnType |
Print
|
pubmed:volume |
77
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
829-33
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9184387-Adult,
pubmed-meshheading:9184387-Anticoagulants,
pubmed-meshheading:9184387-Factor V,
pubmed-meshheading:9184387-Female,
pubmed-meshheading:9184387-Follow-Up Studies,
pubmed-meshheading:9184387-Humans,
pubmed-meshheading:9184387-Male,
pubmed-meshheading:9184387-Middle Aged,
pubmed-meshheading:9184387-Peptide Fragments,
pubmed-meshheading:9184387-Predictive Value of Tests,
pubmed-meshheading:9184387-Protein Precursors,
pubmed-meshheading:9184387-Prothrombin,
pubmed-meshheading:9184387-Pulmonary Embolism,
pubmed-meshheading:9184387-Recurrence,
pubmed-meshheading:9184387-Thromboembolism,
pubmed-meshheading:9184387-Time Factors
|
pubmed:year |
1997
|
pubmed:articleTitle |
Prothrombin fragment F1+2 is not predictive for recurrent venous thromboembolism.
|
pubmed:affiliation |
Department of Internal Medicine, University of Vienna, Austria.
|
pubmed:publicationType |
Journal Article
|